Personalis Stock Intrinsic Value – Upgraded to Buy: Personalis Poised for Earnings Growth, Zacks Rank #2
March 3, 2023
Trending News ☀️
Personalis Stock Intrinsic Value – Recent market data suggest that Personalis ($NASDAQ:PSNL) is set to experience earnings growth in the near future, leading analysts to upgrade their recommendation of the stock to a Zacks Rank #2. This new ranking suggests that the stock could be higher in the near term, which could bring increased investor optimism and higher stock values. Personalis has been making a number of strategic moves and investments that are expected to pay off in the near future.
In addition to the Zacks Rank #2, this has led analysts to predict that the company’s earnings and stock prices are likely to increase significantly in the coming months. As a result, it is likely that Personalis will remain a solid investment choice and could be poised for a strong return in the near future. Investors who recognize this potential and act now may be able to benefit significantly in the short and long term.
Stock Price
On Wednesday, shares of PERSONALIS experienced a hefty dip, opening at $3.0 and closing at $2.6, plunge by 13.0% from the last closing price of $3.0. Despite the discouraging drop, analysts remain bullish on PERSONALIS stock, upgrading it to a ‘Buy’. The data-driven analytics platform holds a Zacks Rank of #2, signaling its affirmative earnings growth outlook. Despite the challenges associated with the current uncertainty of the global economic environment, PERSONALIS is expected to continue to perform well in the coming months, buoyed by its solutions in genomics technologies, existing customer base, and core technology-side partnerships, characterized by its agility and innovation. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Personalis. More…
| Total Revenues | Net Income | Net Margin |
| 65.05 | -113.31 | -174.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Personalis. More…
| Operations | Investing | Financing |
| -70.23 | 52.54 | 1.37 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Personalis. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 292.7 | 74.56 | 4.67 |
Key Ratios Snapshot
Some of the financial key ratios for Personalis are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -0.1% | – | -173.8% |
| FCF Margin | ROE | ROA |
| -184.7% | -30.7% | -24.1% |
Analysis – Personalis Stock Intrinsic Value
We at GoodWhale recently completed an in-depth analysis of PERSONALIS‘s corporate wellbeing. Our proprietary Valuation Line provided us with the fair value of PERSONALIS shares, which is around $11.4. However, we noticed that the market has vastly undervalued the company, with its stock presently traded at $2.6; a 77.2% discount. We believe this is an excellent opportunity for those looking to add PERSONALIS stock to their portfolios. More…
Peers
Personalis Inc is a leading provider of precision medicine solutions. The company offers a suite of products and services that enable its customers to develop and commercialize precision medicine therapies. The company’s products and services include genomic sequencing, bioinformatics, and clinical decision support tools. The company has a strong focus on cancer, rare disease, and pharmacogenomics. Personalis Inc has a number of competitors, including Diaceutics PLC, Charles River Laboratories International Inc, and Biodesix Inc.
– Diaceutics PLC ($LSE:DXRX)
Diaceutics PLC is a diagnostic services company. The company operates a laboratory that provides diagnostic testing services for the detection of genetic diseases. The company also manufactures and sells diagnostic kits and products. The company’s products are used by healthcare professionals in the diagnosis and treatment of genetic diseases.
– Charles River Laboratories International Inc ($NYSE:CRL)
Founded in 1947, Charles River Laboratories International, Inc. is a leading provider of drug discovery, development and manufacturing services to the global pharmaceutical and biotechnology industries. The company has helped advance the science of drug development and commercialization for over 70 years, providing services and products to support customers throughout the drug development process.
Charles River Laboratories International, Inc. has a market cap of $10.47B as of 2022 and a Return on Equity of 13.86%. The company’s market cap is a measure of its value on the stock market, and its ROE is a measure of its profitability. The company’s market cap and ROE both indicate that it is a large and profitable company.
– Biodesix Inc ($NASDAQ:BDSX)
Biodesix Inc is a biotechnology company that develops and commercializes blood-based molecular diagnostic tests for the early detection and treatment of cancer. The company’s tests are based on next-generation sequencing and machine learning.
Biodesix’s market cap is 45.58M as of 2022. The company has a Return on Equity of -655.98%. The company’s tests are based on next-generation sequencing and machine learning.
Summary
Personalis is a biotechnology company focused on developing and commercializing precision medicine products. Analysts have upgraded the stock to a Buy rating and given it a Zacks Rank of 2, indicating that it is currently positioned for earnings growth. Despite this positive news, the stock price of the company dropped on the day of the upgrade, suggesting investors may be uncertain about the future prospects of the company. However, with its promising precision medicine platform and successful track record of creating value, Personalis is well-positioned for continued success in the future.
Related Posts
Recent Posts
